JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
1001 results found
Press releases
2007 statutory financial Statements approved
24/04/08 - 2:00
Investors
Press releases
2011 statutory financial statement approval
23/04/12 - 2:00
Investors
Press releases
2011-2015 Business Plan: a new business wave
17/10/11 - 2:00
Investors
Events
6th annual pan European Bank Of America Merril Lynch Medtech conference
Newsroom
Presentation
9M 2016 Results Presentation
10/11/16
Investors
Presentation
9M 2017 Results Presentation
09/11/17
Investors
Presentation
9M 2018 Results Presentation
07/11/18
Investors
Results
9M 2018 Results Presentation
Investors
Presentation
9M 2019 Results Presentation
06/11/19
Investors
Results
9M 2019 Results Presentation
Investors
Presentation
9M 2020 Results Presentation
11/11/20
Investors
Results
9M 2020 Results Presentation
Investors
Presentation
9M 2021 Results Presentation
11/11/21
Investors
Results
9M 2021 Results Presentation
Investors
Results
9M 2022 Results Presentation
Investors
Results
9M 2023 Results Presentation
Investors
Press releases
A new Group website for DiaSorin: www.diasoringroup.com
06/03/19 - 8:45
Investors
Press releases
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business
13/05/16 - 2:00
Investors
Press releases
Acquisition of MUREX product line
10/03/10 - 1:00
Investors
Press releases
Acquisition of MUREX product line
01/06/10 - 2:00
Investors
Press releases
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment.
05/06/23 - 21:58
Investors
Press releases
Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025.
31/03/25 - 19:36
Investors
Press releases
Agreement in Japan with Advanced Life Science Institute
22/09/08 - 2:00
Investors
Press releases
Agreement with Meridian Inc.
07/07/10 - 2:00
Investors
Press releases
Agreement with Precision System Science Co., LTD
06/05/11 - 2:00
Investors
Press releases
Agreement with Sonic Healthcare on Vitamin D
12/03/12 - 1:00
Investors
Press releases
Aldosterone on LIAISON (available outside the US and Canada only)
29/01/13 - 1:00
Investors
Coverage
ALPHAVALUE
Investors


Press releases
Annex 3F (treasury shares buy back)
24/04/18 - 14:00
Investors
Press releases
Annex 3F (treasury shares buy back July 2018)
03/07/18 - 18:30
Investors
Press releases
Annex 3F (treasury shares buy back June 2018)
03/07/18 - 18:30
Investors
Press releases
Annex 3F (treasury shares buy back May 2018)
04/06/18 - 13:15
Investors
Press releases
Approval of statutory financial statements
27/04/10 - 2:00
Investors

Coverage
BANCA AKROS
Investors
Events
Banca Akros - CEO Lunch
Milan
Investors
Coverage
BANCA IMI
Investors
Coverage
Barclays
Investors
Coverage
Barclays
Investors
Events
Berenberg 2025 Diagnostics Conference
London
Investors
Events
Board of Directors: Annual Report and Consolidated Financial Statements 2009 Approval
Newsroom
Coverage
BofA
Investors
Events
Borsa Italiana - Italian Equity Conference London 2021 – Virtual Edition
Newsroom
Press releases
Cardinal Health: agreement extended to 2014
06/10/11 - 2:00
Investors


Press releases
China approves new prenatal screening product line on LIAISON
09/04/10 - 2:00
Investors
Press releases
Clostridium difficile on LIAISON (available outside the US and Canada only)
07/02/13 - 1:00
Investors
Press releases
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only)
19/12/11 - 1:00
Investors
Press releases
Comment on position Paper on Vitamin D
02/12/10 - 1:00
Investors
Press releases
Communication of total amount of voting rights (7 June 2023)
07/06/23 - 14:40
Investors
Press releases
Communication on total amount of voting rights
16/04/24 - 8:20
Investors
Press releases
Communication on total amount of voting rights
07/08/18 - 8:45
Investors
Press releases
Communication on total amount of voting rights
07/03/19 - 11:45
Investors
Press releases
Communication on total amount of voting rights
05/04/19 - 9:33
Investors
Press releases
Communication on total amount of voting rights
12/04/19 - 8:59
Investors
Press releases
Communication on total amount of voting rights
07/10/19 - 10:20
Investors
Press releases
Communication on total amount of voting rights
06/12/19 - 18:08
Investors
Press releases
Communication on total amount of voting rights
07/02/20 - 8:06
Investors
Press releases
Communication on total amount of voting rights
07/12/20 - 10:35
Investors
Press releases
Communication on total amount of voting rights
07/06/21 - 15:16
Investors
Press releases
Communication on total amount of voting rights (February 7, 2019)
07/02/19 - 15:15
Investors
Press releases
Communication total amount voting rights (record date)
02/06/20 - 14:58
Investors
Press releases
Compensation Commitee-Errata corrige
02/05/13 - 2:00
Investors
Press releases
Conclusion treasury shares buy-back plan
19/04/18 - 21:15
Investors
Press releases
Conclusion treasury shares buy-back plan
03/07/18 - 18:30
Investors
Press releases
Corporate Governance Report at December 2008.
10/04/09 - 2:00
Investors
Press releases
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN
13/02/23 - 22:03
Investors
Coverage
Deutsche Bank
Investors
Presentation
DiaSorin - 9M 2022 Results Presentation
27/10/22
Investors
Press releases
DiaSorin - Annual General Meeting 2016
27/04/17 - 18:45
Investors
Press releases
DiaSorin - Cash flow generation and net profit hit record highs in 2019
11/03/20 - 13:43
Investors
Press releases
DiaSorin - Development of Coronavirus test
10/03/20 - 8:20
Investors
Press releases
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG
25/04/20 - 16:49
Investors
Press releases
DiaSorin - launches the test for Brahms-Sepsis
29/04/15 - 2:00
Investors
Press releases
DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics
17/12/20 - 17:57
Investors
Press releases
DiaSorin 2022-2025 Strategic Plan
Price sensitive16/12/21 - 22:47
Investors
Press releases
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market
30/08/16 - 2:00
Investors
Press releases
DiaSorin and Beckman Coulter sign a distribution agreement for China
20/07/15 - 2:00
Investors
Press releases
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™
09/05/22 - 7:02
Investors
Press releases
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market
06/11/23 - 15:44
Investors
Press releases
DiaSorin and Labcorp extend strategic business relationship
11/05/11 - 2:00
Investors
Press releases
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
08/09/20 - 7:31
Investors
Press releases
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom
09/10/18 - 11:35
Investors
Press releases
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease
05/06/19 - 7:38
Investors
Press releases
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays
22/06/17 - 19:45
Investors
Press releases
DiaSorin and TECAN to collaborate in new platform development
23/06/17 - 9:30
Investors
Press releases
Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay
27/09/24 - 7:35
Investors
Press releases
Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®
11/11/24 - 7:38
Investors
Press releases
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel
08/03/22 - 7:13
Investors
Press releases
DiaSorin announces completion of the Acquisition of Luminex Corporation
14/07/21 - 15:05
Investors
Press releases
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028
28/04/21 - 7:54
Investors
Press releases
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028
Price sensitive28/04/21 - 7:54
Investors
Press releases
DiaSorin announces its strategic collaboration with Lumos Diagnostics
Price sensitive06/04/21 - 7:06
Investors
Press releases
Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023
25/01/24 - 7:48
Investors
Press releases
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone
06/08/20 - 7:25
Investors
Press releases
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients
30/06/20 - 7:25
Investors


Press releases
DiaSorin became a member of the ISBT
17/02/12 - 1:00
Investors
Press releases
Diasorin Board of Directors approves 2024-2027 Business Plan
Price sensitive15/12/23 - 17:38
Investors
Press releases
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
31/07/19 - 13:00
Investors
Press releases
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
Price sensitive11/11/21 - 16:56
Investors
Press releases
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Price sensitive16/03/22 - 17:39
Investors
Press releases
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test
Price sensitive18/09/21 - 8:16
Investors
Press releases
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay
Price sensitive20/05/22 - 7:08
Investors
Press releases
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay
07/07/20 - 7:22
Investors
Press releases
DiaSorin commercializes molecular reagent for monkeypox virus
07/11/22 - 7:12
Investors
Press releases
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
29/09/17 - 14:15
Investors
Press releases
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant
30/11/21 - 19:10
Investors
Press releases
DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME
22/07/14 - 2:00
Investors
Press releases
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM
26/05/23 - 7:10
Investors
Press releases
DiaSorin COVID-19 test has received FDA Emergency Use Authorization
20/03/20 - 7:28
Investors
Press releases
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit
21/09/17 - 12:45
Investors
Press releases
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test
28/03/18 - 18:45
Investors
Press releases
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China
23/09/20 - 7:16
Investors
Press releases
DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018
28/01/14 - 1:00
Investors
Press releases
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES
05/10/22 - 6:37
Investors
Press releases
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016
10/11/16 - 1:00
Investors
Press releases
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019
09/05/19 - 13:14
Investors
Press releases
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018
07/11/18 - 13:00
Investors
Press releases
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow
08/05/17 - 19:30
Investors
Press releases
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
13/05/20 - 13:15
Investors
Press releases
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017
03/08/17 - 14:45
Investors
Press releases
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay
12/06/20 - 7:30
Investors
Press releases
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19
17/04/20 - 18:25
Investors
Press releases
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S.
Price sensitive29/03/21 - 7:02
Investors
Press releases
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance
29/12/20 - 18:22
Investors
Press releases
DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation
24/03/15 - 1:00
Investors
Press releases
DiaSorin in India: JV with Trivitron Healthcare
30/07/12 - 2:00
Investors
Press releases
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology
21/04/21 - 7:02
Investors
Press releases
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia
14/07/16 - 2:00
Investors
Press releases
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia
12/06/18 - 14:15
Investors
Presentation
DiaSorin Investor Day 2021 Presentation
17/12/21
Investors
Press releases
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection
Price sensitive25/05/21 - 7:03
Investors
Press releases
DiaSorin launches 3 new primer pairs for use in molecular testing
21/12/18 - 11:30
Investors
Press releases
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS
28/07/17 - 14:45
Investors
Press releases
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test
12/12/17 - 13:15
Investors
Press releases
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL
06/05/19 - 15:19
Investors
Press releases
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market
31/01/19 - 22:30
Investors
Press releases
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform
27/07/18 - 12:00
Investors
Press releases
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP
10/07/17 - 13:30
Investors
Press releases
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST
02/11/16 - 1:00
Investors
Press releases
DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL
09/12/14 - 1:00
Investors
Press releases
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market
21/02/17 - 11:30
Investors
Press releases
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET
22/10/19 - 14:10
Investors
Press releases
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark
23/11/21 - 7:10
Investors
Press releases
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET
30/10/19 - 9:55
Investors
Press releases
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET
11/11/19 - 9:46
Investors
Press releases
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States
03/01/19 - 13:30
Investors
Press releases
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market
17/10/18 - 11:51
Investors
Press releases
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States
19/11/18 - 15:00
Investors
Press releases
DiaSorin launches Simplexa VZV Direct molecular assay in the european market
12/10/18 - 11:47
Investors
Press releases
DiaSorin launches the anaemia panel on Liaison XL in Europe
03/04/19 - 10:32
Investors
Press releases
DiaSorin launches the EHEC Toxins test on stool samples
25/10/13 - 2:00
Investors
Press releases
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E
15/06/21 - 6:56
Investors
Press releases
DiaSorin launches the hCG test on its LIAISON XL in the US
24/09/13 - 2:00
Investors
Press releases
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE
26/01/17 - 12:45
Investors
Press releases
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET
27/11/19 - 7:59
Investors
Press releases
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark
13/06/23 - 15:18
Investors
Press releases
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark
Price sensitive20/04/21 - 18:58
Investors
Press releases
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease
17/07/23 - 7:03
Investors
Press releases
Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark
09/09/24 - 13:11
Investors
Press releases
DiaSorin launches the new Helicobacter pylori IgG CLIA test
07/06/16 - 2:00
Investors
Press releases
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality
16/05/17 - 13:00
Investors
Press releases
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders
23/05/17 - 11:45
Investors
Press releases
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen
17/09/18 - 11:28
Investors
Press releases
DiaSorin launches the new test for Parvovirus on LIAISON IAM
20/06/13 - 2:00
Investors
Press releases
DiaSorin launches the new test for PTH on LIAISON
18/02/14 - 1:00
Investors
Press releases
DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM
24/07/13 - 2:00
Investors
Press releases
Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark
18/03/25 - 11:54
Investors
Press releases
DiaSorin launches the stool test for Adenovirus on LIAISON
18/09/14 - 2:00
Investors
Press releases
DiaSorin launches the test for Calprotectin
14/01/15 - 1:00
Investors
Press releases
DiaSorin launches the test for Campylobacter
28/05/15 - 2:00
Investors
Press releases
DiaSorin launches the test for Cytomegalovirus on LIAISON IAM
09/01/14 - 1:00
Investors
Press releases
DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM
30/06/14 - 2:00
Investors
Press releases
DiaSorin launches the test for HIV HT on LIAISON
07/10/14 - 2:00
Investors
Press releases
DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas)
10/10/13 - 2:00
Investors
Press releases
DiaSorin launches the test for Rotavirus on stool sample
11/02/14 - 1:00
Investors
Press releases
DiaSorin launches the test for Vitamin D 1,25 on LIAISON
03/06/14 - 2:00
Investors
Press releases
DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON
28/06/13 - 2:00
Investors
Press releases
DiaSorin launches the tests for Bordetella pertussis
14/04/15 - 2:00
Investors
Press releases
DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias
09/09/15 - 2:00
Investors
Press releases
DiaSorin launches VZV Direct molecular test in Europe
24/09/19 - 10:10
Investors
Press releases
DiaSorin launches VZV DIRECT molecular test in the United States
29/05/19 - 15:06
Investors
Press releases
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients
26/10/20 - 18:30
Investors
Press releases
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test
11/01/21 - 18:43
Investors
Press releases
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market
23/02/21 - 6:11
Investors
Press releases
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex
09/07/21 - 7:34
Investors
Press releases
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil
11/07/13 - 2:00
Investors
Press releases
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China
24/01/14 - 1:00
Investors
Press releases
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY
22/08/16 - 2:00
Investors
Presentation
DiaSorin Presentation - Planned Acquisition of Focus Diagnostics Product Business
30/03/16
Investors
Press releases
DiaSorin presents its 2017-2019 Industrial Plan
26/06/17 - 9:45
Investors
Press releases
DiaSorin presents its 2019-2022 Industrial Plan
10/06/19 - 18:23
Investors
Press releases
DiaSorin presents the 2015-2017 industrial plan
12/05/15 - 2:00
Investors
Press releases
Diasorin: Publication of the documents for the Ordinary Shareholders' Meeting scheduled on April 24, 2024
15/03/24 - 17:14
Investors
Press releases
Diasorin: Publication of the documents for the Shareholders' Meeting scheduled on September 4, 2024
29/07/24 - 17:35
Investors
Press releases
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative
13/04/22 - 16:43
Investors
Press releases
DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR
Price sensitive29/07/24 - 15:55
Investors
Press releases
DiaSorin received BARDA funding to develop a rapid COVID-19 test
13/03/20 - 17:16
Investors
Press releases
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test
30/03/21 - 7:01
Investors
Press releases
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market
01/12/20 - 6:33
Investors
Press releases
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market
01/10/20 - 7:45
Investors
Press releases
Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX®
18/04/25 - 18:11
Investors
Press releases
DiaSorin receives authorization for the distribution of Zika IgM test in Europe
21/04/17 - 18:45
Investors
Press releases
Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel
Price sensitive03/03/24 - 19:32
Investors
Press releases
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test
14/07/22 - 20:00
Investors
Press releases
Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX®
05/06/24 - 5:07
Investors
Press releases
Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2
16/05/24 - 19:56
Investors
Press releases
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer
29/11/21 - 7:06
Investors
Press releases
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay
16/12/19 - 14:10
Investors
Press releases
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis)
05/04/18 - 12:00
Investors
Press releases
Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument
16/07/24 - 8:31
Investors
Press releases
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test
06/04/17 - 18:00
Investors
Press releases
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2
Price sensitive21/05/21 - 7:02
Investors
Press releases
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant
Price sensitive13/01/22 - 7:24
Investors
Press releases
Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance
Price sensitive05/11/24 - 16:27
Investors
Press releases
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex
Price sensitive30/07/21 - 12:57
Investors
Press releases
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS
29/09/17 - 15:00
Investors
Presentation
DiaSorin Roadshow Presentation - November 2018
12/11/18
Investors
Presentation
DiaSorin Roadshow Presentation - September 2018
31/08/18
Investors
Presentation
DiaSorin Roadshow Presentation - September 2022
13/09/22
Investors
Press releases
DiaSorin signes a 5-year agreement with Roche
29/10/13 - 1:00
Investors
Press releases
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
Price sensitive14/05/21 - 16:10
Investors
Press releases
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ
03/06/21 - 7:47
Investors
Press releases
DiaSorin signs an agreement with Seegene
02/04/13 - 2:00
Investors
Press releases
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime
30/01/18 - 11:45
Investors
Press releases
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology
02/03/20 - 8:04
Investors
Press releases
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance
Price sensitive17/03/23 - 22:05
Investors
Press releases
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance
09/11/22 - 7:04
Investors
Press releases
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens
16/09/20 - 7:25
Investors
Press releases
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE
Price sensitive14/09/22 - 0:29
Investors
Press releases
Diasorin S.p.A. - Shareholders' Meeting September 4, 2024
04/09/24 - 11:36
Investors
Press releases
DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events
05/09/24 - 11:17
Investors
Press releases
DiaSorin S.p.A.- Update 2024 Annual Calendar of Corporate Events
04/04/24 - 9:34
Investors
Press releases
DiaSorin starts selling Vitamin D in Japan
28/07/16 - 2:00
Investors
Press releases
Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA
13/03/24 - 10:23
Investors
Press releases
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028
28/04/21 - 17:46
Investors
Press releases
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028
Price sensitive28/04/21 - 17:46
Investors
Presentation
Diasorin "The Right Test At The Right Time" Presentation
02/08/24
Investors
Press releases
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
25/07/17 - 21:00
Investors
Press releases
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business
30/03/16 - 2:00
Investors
Press releases
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
Price sensitive11/04/21 - 19:47
Investors
Presentation
Diasorin to Present at Jefferies London Healthcare Conference 2024
20/11/24
Investors
Presentation
Diasorin to present at J.P. Morgan Healthcare Conference 2025
15/01/25
Investors
Press releases
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com
24/10/23 - 15:03
Investors
Press releases
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study
09/07/20 - 7:27
Investors
Press releases
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
01/10/20 - 7:32
Investors
Press releases
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market
Price sensitive20/05/21 - 8:27
Investors
Press releases
DiaSorin's stocks listed in the FTSE MIB
04/12/18 - 8:00
Investors

Press releases
Dividend may be distributed in June
20/12/10 - 1:00
Investors
Events
Draft Statutory Financial and Consolidated Financial Statements 2012 approval
Newsroom
Coverage
EQUITA SIM
Investors
Coverage
EXANE BNP PARIBAS
Investors
Press releases
Execution of the project for the redefinition of the corporate structure of DiaSorin
07/06/22 - 18:06
Investors
Press releases
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay
07/09/20 - 18:22
Investors
Press releases
FDA approves 1,25 Vitamin D in the US market
16/12/14 - 1:00
Investors
Press releases
FDA approves the Aldosterone assay
17/04/13 - 2:00
Investors
Press releases
FDA approves the LIAISON XL
26/01/11 - 1:00
Investors
Press releases
FDA clearance for 25 OH Vitamin D on LIAISON
02/02/12 - 1:00
Investors
Press releases
FDA clearance to five LIAISON products
08/01/09 - 1:00
Investors
Press releases
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l.
04/04/22 - 18:12
Investors
Presentation
FY 2011 Results Presentation
09/03/12
Investors
Presentation
FY 2012 Results Presentation
08/03/13
Investors
Presentation
FY 2013 Results Presentation
06/03/14
Investors
Presentation
FY 2014 Results Presentation
30/03/15
Investors
Results
FY 2014 Results Presentation
Investors
Presentation
FY 2015 Results Presentation
17/03/16
Investors
Results
FY 2015 Results Presentation
Investors
Presentation
FY 2016 Results Presentation
08/03/17
Investors
Results
FY 2016 Results Presentation
Investors
Presentation
FY 2017 Results Presentation
07/03/18
Investors
Results
FY 2017 Results Presentation
Investors
Presentation
FY 2018 Results Presentation
14/03/19
Investors
Results
FY 2018 Results Presentation
Investors
Presentation
FY 2019 Results Presentation
11/03/20
Investors
Results
FY 2019 Results Presentation
Investors
Presentation
FY 2020 Results Presentation
11/03/21
Investors
Results
FY 2020 Results Presentation
Investors
Presentation
FY 2021 Results Presentation
16/03/22
Investors
Results
FY 2021 Results Presentation
Investors
Presentation
FY 2022 Results Presentation
27/03/23
Investors
Results
FY 2022 Results Presentation
Investors